[논문-IMGT] Evading Doxorubicin‐Induced Systemic Immunosuppression Using…
페이지 정보
- Date : 22-12-01 08:37
- Views : 1,431 time
관련링크
본문
"Evading Doxorubicin‐Induced Systemic Immunosuppression Using Ultrasound‐Responsive Liposomes Combined with Focused Ultrasound"
Pharmaceutics 2022, 14, 2603.
https://doi.org/10.3390/pharmaceutics14122603
Published: 25 November 2022
Jeongjin Lee, Wooram Um, Hyungwon Moon, Hyeyeon Joo, Yeari Song, Minsung Park, Been Yoon, Hyun-Ryoung Kim, and Jae Hyung Park
[Abstract]
Doxorubicin (DOX) is a representative anticancer drug with a unique ability to induce
immunogenic cell death of cancer cells. However, undesired toxicity on immune cells has remained
a significant challenge, hindering the usage of DOX in cancer immunotherapy. Here, we report
a combined therapy to avoid the off-target toxicity of DOX by adapting ultrasound-responsive
liposomal doxorubicin and focused ultrasound exposure. Histological analysis demonstrated that
the combined therapy induced less hemosiderosis of splenocytes and improved tumor infiltration
of cytotoxic T lymphocytes. Additionally, in vivo therapeutic evaluation results indicate that the
combined therapy achieved higher efficacy when combined with PD-1 immune-checkpoint blockade
therapy by improving immunogenicity.